This segment focuses on the research, development, and commercialization of innovative therapies for autoimmune diseases. RemeGen's lead product in this area is Telitacicept (RC18), a novel fusion protein targeting both BLyS and APRIL. Clinical trials are underway for systemic lupus erythematosus, neuromyelitis optica spectrum disorder, rheumatoid arthritis, IgA nephritis, Sjögren's syndrome, multiple sclerosis, and myasthenia gravis. The goal is to provide targeted treatments that improve patient outcomes and quality of life. The company leverages its expertise in biologics and protein engineering to develop differentiated therapies with improved efficacy and safety profiles. Regulatory approvals and market access strategies are key components of this segment's growth potential.

RemeGen's oncology segment is dedicated to developing and commercializing innovative therapies for various cancers. A key product is Disitamab Vedotin (RC48), an antibody-drug conjugate (ADC) targeting HER2. The company is also developing RC98 for the treatment of various cancers. Research and development efforts focus on ADCs, monoclonal antibodies, and other biologics. Clinical trials are conducted to evaluate the safety and efficacy of these therapies across different solid tumor types. The segment aims to address unmet medical needs in cancer treatment by providing targeted therapies with improved efficacy and reduced toxicity. Strategic partnerships and collaborations are essential for expanding the pipeline and accelerating the development of novel oncology therapies.

This segment is focused on developing innovative therapies for ophthalmic diseases with unmet medical needs. RemeGen's lead product in this area is RC28, which has completed Phase 1 clinical trials for the treatment of wet age-related macular degeneration, diabetic macular edema, and diabetic retinopathy. The company is leveraging its expertise in biologics and protein engineering to develop targeted therapies that improve patient outcomes and quality of life. Research and development efforts focus on monoclonal antibodies and other biologics. Clinical trials are conducted to evaluate the safety and efficacy of these therapies across different ophthalmic diseases. The segment aims to address unmet medical needs in ophthalmic treatment by providing targeted therapies with improved efficacy and reduced toxicity.